Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: Retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 32, Issue 8, 2003, Pages 801-807

  Yanada, M ^a   Yamamoto, K ^a   Emi, N ^a   Naoe, T ^a   Suzuki, R ^b   Taji, H ^b   Iida, H ^c   Shimokawa, T ^d   Kohno, A ^e   Mizuta, S ^f   Maruyama, F ^g   Wakita, A ^h   Kitaori, K ⁱ   Yano, K ^j   Hamaguchi, M ^k   Hamajima, N ^a   Morishima, Y ^b   Kodera, Y ⁱ   Sao, H ^c   Morishita, Y ^e  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Meitetsu Hospital   (Japan)

^d Nagoya Ekisaikai Hospital   (Japan)

^e JA Aichi Koseiren Showa Hospital   (Japan)

^f ANJO KOSEI HOSPITAL   (Japan)

^g FUJITA HEALTH UNIVERSITY   (Japan)

^h NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

ⁱ JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^j HAMAMATSU MEDICAL CENTER   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

Antigenemia; Cytomegalovirus; Ganciclovir; Hematopoietic stem cell transplantation; Pre emptive therapy

Indexed keywords

GANCICLOVIR; VIRUS ANTIGEN;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; GASTROENTERITIS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEPATITIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS REACTIVATION; WHOLE BODY RADIATION;

EID: 11144354219     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704232     Document Type: Article

References (27)

1. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
2. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063-4071.
3. Nguyen Q, Champlin R, Giralt S et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28: 618-623.
4. Machado CM, Menezes RX, Macedo MC et al. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 2001; 28: 1053-1059.
5. Salzberger B, Bowden RA, Hackman RC et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood 1997; 90: 2502-2508.
6. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998; 11: 533-554.
7. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
8. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867-874.
9. Ljungman P, Lore K, Aschan J et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583-587.
10. Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763.
11. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
12. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 1993; 119: 207-214.
13. Enright H, Haake R, Weisdorf D et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993; 55: 1339-1346.
14. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand? Blood 1994; 83: 2392-2398.
15. Bacigalupo A, Tedone E, Isaza A et al. CMV-antigenemia after allogeneic bone marrow transplantation: Correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1995; 16: 155-161.
16. Takenaka K, Gondo H, Tanimoto K et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 241-248.
17. Ljungman P, Aschan J, Lewensohn-Fuchs I et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66: 1330-1334.
18. Osarogiagbon RU, Defor TE, Weisdorf MA et al. CMV antigenemia following bone marrow transplantation: Risk factors and outcomes. Biol Blood Marrow Transplant 2000; 6: 280-288.
19. Morishima Y, Kodera Y, Hirabayashi N et al. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A,B,DR-compatible unrelated donors among Japanese. Bone Marrow Transplant 1995; 15: 235-239.
20. Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206.
21. Kodera Y, Morishima Y, Kato S et al. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: Confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant 1999; 24: 995-1003.
22. Avery RK, Adal KA, Longworth DL et al. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000; 26: 763-767.
23. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005-1011.
24. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-1607.
25. Verdonck LF, Dekker AW, Rozenberg-Arska M et al. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 1997; 24: 901-907.
26. Shimokawa T, Morishima Y, Kitaori K et al. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors. Int J Hematol 1999; 70: 119-126.
27. Kanda Y, Mineishi S, Saito T et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation. Transplantation 2002; 73: 568-572.